Canadian cancer biotech ProNAi Therapeutics sets terms for $101 million IPO - (NASDAQ via NewsPoints Desk)

  • NASDAQ reported that ProNAi Therapeutics, which is developing cancer therapies based on DNA interference, announced terms for its IPO.
  • Specifically, the company plans to raise $101 million by offering 6.7 million shares at a price ranging from $14 to $16.

To read more NewsPoints articles, click here.